To date, there are no reliable data regarding the actual treatment received by women with refractory obstetric antiphospholipid syndrome (OAPS). The aim of this study was to assess current clinical evidence and new trends in the treatment of refractory OAPS.
Methods
A non-systematic but comprehensive literature search using relevant keywords was made to identify relevant articles published in English from different computerized databases: PubMed (Medline), Google Scholar electronic database search and The Cochrane Library, from January 2000 to March 2012. Studies on the treatment of poor obstetric outcomes in women with OAPS were included. Prospective randomized clinical trials, cohort studies, reviews, systematic reviews and meta-analysis were retrieved.
Results
A total of 130 articles were finally selected for this review, including 17 randomized clinical trials and four meta-analyses. The majority of articles were non-randomized original papers and basic and clinical reviews.
Conclusion
Up to 20% of women with OAPS do not receive the currently recommended therapeutic regimen. Unfortunately, well-designed studies regarding the usefulness of new drugs in refractory OAPS are scarce. Hydroxychloroquine and low-dose prednisolone appear to be useful when added to standard therapy. Current data do not support the use of intravenous immunoglobulins in this field. The role played by double anti-aggregant therapy, fondaparinux, vitamin D, pentoxifylline and TNF-targeted therapies should be tested in well-designed studies.
YamaguchiYNoriyukiNKaburakiJ. Excessive exposure to anionic surfaces maintains autoantibody response to B2-glycoprotein I in patients with antiphospholipid syndrome. Blood2007; 110: 4312–4318.
2.
MiyakisSLockshinMDAtsumiT. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost2006; 4: 295–306.
3.
Alijotas-ReigJ. Towards the comprehension of the heterogeneity of clinical manifestations related with antiphospholipid antibodies. Med Clin [Barc]2005; 125: 187–189.
4.
BoffaM-CBoinotCde CarolisS. Laboratory criteria of the obstetrical antiphospholipid syndrome [APS]. Data from a multicentre prospective European women cohort. Thromb Haemost2009; 102: 25–28.
5.
MeroniPRaschiEGrossiC. Obstetric and vascular APS: Same autoantibodies but different diseases?Lupus2012; 21: 708–710.
6.
LassereMEmpsonM. Treatment of antiphospholipid syndrome in pregnancy – a systematic review of randomized therapeutic trials. Thromb Res2004; 114: 419–426.
7.
DanzaARuiz-IrastorzaGKhamashtaMA. Antiphospholipid syndrome in obstetrics. Best Pract Res Clin Obstet Gynecol2012; 26: 65–76.
8.
ScobleTWijetillekaSKhamashtaMA. Management of refractory anti-phospholipid syndrome. Autoimmunity Rev2011; 10: 669–673.
9.
BatesSM. Consultative hematology: the pregnant patient pregnancy loss. Haematology Am Soc Hematol Educ Program2010; 2010: 166–172.
10.
SimchenMJDulitzkiMRofeG. High positive antibody titers and adverse pregnancy outcome in women with antiphospholipid syndrome. Acta Obstet Gynecol Scand2011; 90: 1428–1433.
11.
Di PrimaFAFValentiOHyseniE. Antiphospholipid syndrome during pregnancy: the state of the art. J Perinatal Med2011; 5: 41–53.
12.
Alijotas-ReigJFerrer-OliverasR. The European Registry on Obstetric Antiphospholipid Syndrome [EUROAPS]: A preliminary first year report. Lupus2012; 21: 766–768.
13.
de JesusGRdos SantosFCOliveiraCS. Management of obstetric antiphospholipid syndrome. Curr Rheumatol Rep2012; 14: 79–86.
14.
CohenDBergerSPSteup-BeekmanMA. Diagnosis and management of antiphospholipid syndrome. BMJ2010; 340: 1125–1132.
15.
Ruiz-IrastorzaGEgurbideMVUgaldeJ. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch Intern Med2004; 164: 77–78.
CerveraRPietteJCFontJ. Antiphospholipid syndrome: clinical and immunologic manifestations and pattern of disease expression in a cohort of 1,000 patients. Arthritis Rheum2002; 46: 1019–1027.
20.
Ferrer-OliverasRLlurbaECabero-RouraL. Prevalence and clinical usefulness of antiphospholipid and anti-cofactor antibodies in different Spanish preeclampsia subsets. Lupus2012; 21: 257–263.
AshersonRACerveraRShepshelovichD. Non-thrombotic manifestations of the antiphospholipid syndrome: away from thrombosis?J Rheumatol2006; 33: 1038–1044.
27.
Alijotas-ReigJVilardell-TarrésM. Is obstetric antiphospholipid syndrome a primary nonthrombotic, proinflammatory, complement-mediated disorder related to antiphospholipid antibodies?Obstet Gynecol Surv2010; 65: 39–45.
28.
OutHJKooijmanCDBruinseHW. Histopathological findings in placenta from patients with intra-uterine fetal death and antiphospholipid antibodies. Eur J Obstet Gynaecol Reprod Biol1991; 195: 211–220.
29.
GirardiGRedechaPSalmonJE. Heparin prevents antiphospholipid-induced fetal loss by inhibiting complement activation. Nature Med2004; 10: 1222–1226.
30.
GirardiGBermanJRedechaP. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest2003; 112: 1644–1654.
31.
HolersVMGirardiGMoL. Complement C3 activation is required for antiphospholipid antibody induced fetal loss. J Exp Med2002; 195: 211–220.
32.
MeroniPLdi SimoneNTestoniC. Antiphospholipid antibodies as cause of pregnancy loss. Lupus2004; 13: 649–652.
33.
MagidMSKaplanCSammaritanoLR. Placental pathology in systemic lupus erythematosus: a prospective study. Am J Obstet Gynecol1998; 179: 226–234.
34.
HolmesCHSimpsonKL. Complement and pregnancy: new insights into the immunobiology of the fetal-maternal relationship. Balliere’s Clin Obstet Gynecol1992; 6: 439–459.
35.
CunninghamDSTichenorJRJr. Decay-accelerating factor protects human trophoblast from complement-mediated attack. Clin Immunol Immunopathol1995; 74: 156–161.
36.
Alijotas-ReigJ. The immunological puzzle of recurrent miscarriage. Curr Immunol Rev2009; 5: 175–186.
37.
QuenbySBatesMDoigT. Pre-implantation endometrial leukocytes in women with recurrent miscarriage. Hum Reprod1999; 14: 2386–2391.
38.
TuckermanELairdSPrakashA. Prognostic value of the measurement of uterine natural killer cells in the endometrium of women with recurrent miscarriage. Hum Reprod2007; 22: 2208–2213.
39.
Szekeres-BarthoJFaustZVargaP. The immunological pregnancy protective effect of progesterone is manifested via controlling cytokine production. Am J Reprod Immunol1996; 35: 348–351.
40.
CarpHJAShoenfeldY. Recurrent spontaneous abortions in antiphospholipid syndrome: natural killer cells - an additional mechanism in a multifactorial process. Rheumatology2007; 46: 1517–1519.
Szekeres-BarthoJKilarFFalkayG. The mechanism of the inhibitory effect of progesterone on lymphocyte cytotoxicity: I. Progesterone-treated lymphocytes of healthy pregnant women release a factor inhibiting cytotoxicity and prostaglandin synthesis. Am J Reprod Immunol Microbiol1985; 9: 15–19.
43.
FaustZLaskarinGRukavinaD. Progesterone induced blocking factor inhibits degranulation of NK cells. Am J Reprod Immunol1999; 42: 71–75.
44.
CarpHJAShoenfeldY. Recurrent spontaneous abortions in antiphospholipid syndrome: natural killer cells-an additional mechanism in a multifactorial process. Rheumatology2007; 46: 1517–1519.
45.
PerriconeCDe CarolisCGiaccomelliR. High levels of NK cells in the peripheral blood of patients affected with anti-phospholipid syndrome and recurrent spontaneous abortion: a potential new hypothesis. Rheumatology2007; 46: 1574–1578.
46.
BermanJGirardiGSalmonJE. TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol2005; 174: 1222–1226.
47.
MeroniPLBorghiMORaschiE. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol2011; 7: 330–339.
48.
Di SimoneNMeroniPLD’AstaM. Pathogenic role of anti-β2-glycoprotein I antibodies on human placenta: functional effects related to implantation and roles of heparin. Hum Reprod Update2007; 13: 189–196.
49.
Di SimoneNDi NicuoloFD’IppolitoS. Antiphospholipid antibodies affect human endometrial angiogenesis. Biol Reprod2010; 83: 212–219.
50.
D’IppolitoSMaranaRDi NicuoloF. Effect of low molecular weight heparins on antiphospholipid antibodies-mediated inhibition of endometrial angiogenesis. PLoS ONE2012; 7: e29660–e29660.
51.
DerksenRHde GrootPG. Towards evidence-based treatment of thrombotic antiphospholipid syndrome. Lupus2010; 19: 470–474.
52.
Ruiz-IrastorzaGCuadradoMRuiz-ArruzaI. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report to a Task Force at the 13th International Congress on Antiphospholipid Antibodies. Lupus2011; 20: 206–218.
53.
BatesSMGreerIAPabingerI. Venous thromboembolism, thrombophilias, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [8th edn]. Chest2008; 133 (6 Suppl): 844S–886S.
54.
BatesSM. Consultative hematology: the pregnant patient pregnancy loss. Haematology Am Soc Hematol Educ Program2010; 2010: 166–172.
55.
EspinosaRGPierangeliSSGharaviAE. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholid antibodies. Thromb Haemost2002; 87: 518–522.
56.
EdwardsMHPierangeliSSLiuX. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation1997; 96: 4380–4384.
57.
HillsFAAbrahamsVMGonzalez-TimónB. Heparin prevents programmed cell death in human trophosblast. Mol Hum Reprod2006; 12: 237–243.
58.
OberkerschRAttoresiACalabreseGC. Low-molecular-weight heparin inhibition in classical complement activation pathway during pregnancy. Thromb Res2010; 125: e240–245.
59.
LimW. Complement and the antiphospholipid syndrome. Curr Opinion Hematol2011; 18: 361–365.
60.
GirardiGRedechaPSalmonJE. Heparin prevents antiphospholipid-induced fetal loss by inhibiting complement activation. Nat Med2004; 10: 1226–1226.
61.
CarrJAChoJS. Low molecular weight heparin suppresses tumor necrosis factor expression from deep vein thrombosis. Ann Vasc Surg2007; 21: 50–55.
62.
GirardiGRedechaPSalmonJE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med2004; 10: 1222–1226.
63.
SamamaMMGerotziafasGT. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide [fondaparinux]. Thromb Res2003; 109: 1–11.
64.
BanzatoAFrassonRAcqusalienteL. Circulating B2glycoprotein I-IgG anti-B2glycoprotein I immunocomplexes in patients with definite antiphospholipid syndrome. Lupus2012; 21: 784–786.
65.
AmaraUFliertMARittirschD. Molecular intercommunications between the complement and coagulation systems. J Immunol2010; 185: 5268–5236.
66.
Da Pozzo E, Barsoti MC, Benditelli S, et al. Differential effects of fondaparinux and bemiparin on angiogenic and vasculogenesis-like processes. Thromb Res 2012; 130: e113–122.
James DG and Williams WJ. Sarcoidosis and other granulomatous disorders. In: Smith LLH (ed.) Major problems in internal medicine, Philadelphia: W.B. Saunders Co, 1985; 24: 1–254.
71.
Rynes RI. Antimalarial drugs. In: Kelley WN, Harris ED, Ruddyn S and Sledge CB (eds), Textbook of rheumatology, 4th ed. Philadelphia: W.B. Saunders, 1993, pp. 731--742.
72.
RandJHWuXXLapinskiR. Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. Blood2004; 104: 2783–2790.
73.
HuntBJWuXXde LaatB. Resistance to annexin A5 anticoagulant activity in women with histories for obstetric antiphospholipid syndrome. Am J Obstet Gynecol2011; 205: 485.e17–23.6.
74.
RandJHWuXXQuinnAS. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood2010; 115: 2292–229.
75.
RandJHWuXXQuinn As. Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay. Am J Pathol2003; 163: 1193–1200.
76.
RandJWuXQuinnA. The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis. Lupus2010; 19: 460–469.
77.
ESPRIT StudyGroupHalkesPHvan GijnJKappelleLJ. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin [ESPRIT]: randomised controlled trial. Lancet2006; 367: 1665–1673.
78.
LevineSRBreyRLJosephCL. Risk of recurrent thromboembolic events in patients with focal cerebral ischemia and antiphospholipid antibodies. The Antiphospholipid Antibodies in Stroke Study Group. Stroke1992; 23(2 Suppl): 129–132.
79.
GeorgeEMCockrellKAdairTH. Regulation of sFlt-1 and VEGF secretion by adenosine under hypoxic condition in rat placental villous explants. Am J Physiol Regul Integr Comp Physiol2010; 299: R1629–1633.
80.
DuleyLHenderson-SmartDJMeherS. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane database Syst Rev2007; 18: CD004659–CD004659.
81.
VivaldiPAndreottiCMazzoniC. A primitive catastrophic antiphospholipid syndrome. Haematologica1994; 79: 173–176.
82.
Burcoglu-O’RalAErkanDAshersonR. Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator. J Rheumatol2002; 29: 2006–2011.
83.
LubbeWButlerWPalmerS. Fetal survival after prednisone suppression of maternal lupus anticoagulant. Lancet1983: 1: 1361–1363.
84.
Axelrod L. Glucocortiocoids. In: Kelley NK, Harris ED, Ruddy S, Sledge C (eds) Textbook of rheumatology. 4th ed. Philadelphia, W.B. Saunders Co, 1993, vol 1, pp.779–796.
85.
SneidermanCWilsonJ. Effects of corticosteroids on complement and the neutrophil polymorphonuclear leukocyte. Transplant Proc1975; 1: 1361–1363.
LaskinCABombardieriCHannahME. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med1997; 337: 148–153.
89.
BenediktssonRCalderAEdwardsC. Placental 11 beta-hydroxysteroid dehydrogenase: a key regulator of fetal glucocorticoid exposure. Clin Endocrinol [Oxf]1997; 46: 161–166.
90.
Akther A, Faridi RM, Das V, et al. In vitro up-regulation of HLA-G using dexamethasone and hydrocortisone in first-trimester trophoblast cells of women experiencing recurrent miscarriage. Tissue Antigens 2012; 80: 126–135.
PerriconeRDe CarolisCKröeglerB. Intravenous immunoglobulin therapy in pregnant patients affected with systemic lupus erythematosus and recurrent spontaneous abortion. Rheumatology2008; 47: 646–651.
94.
CerveraR. Update on the diagnosis, treatment, and prognosis of the catastrophic antiphospholipid syndrome. Curr Rheumatol Rep2010; 12: 70–76.
95.
TuthillJKhamashtaM. Management of antiphospholipid syndrome. J Autoimmun2009; 33: 92–98.
96.
TrioloGFerranteACicciaF. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulins in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. Arthritis Rheum2003; 48: 728–731.
97.
BranchDPeacemanADruzinM. A multicenter placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. Am J Obstet Gynecol2000; 182: 122–127.
98.
DendrinosSSakkasEMakrakisE. Low-molecular-weight heparin versus intravenous immunoglobulin for recurrent abortion associated with antiphospholipid antibody syndrome. Int J Gynaecol Obstet2009; 104: 223–225.
99.
Lopera-VallejoAFAlijotas-ReigJ. Antiphospholipid antibodies and recurrent implantation failure in in-vitro fertilization. The debate goes on. Med Clin [Barc]2011; 137: 697–701.
100.
SzodorayPBacskóGLakosG. Combined therapy in pregnancy with primary antiphospholipid syndrome. Orv Hetil2003; 144: 2411–2413. [Article in Hungarian].
101.
VaqueroELazzarinNValensiseH. Pregnancy outcome in recurrent spontaneous abortion associated with antiphospholipid antibodies: a comparative study of intravenous immunoglobulin versus prednisolone plus low-dose aspirin. Am J Reprod Immunol2001; 45: 174–179.
102.
CarpHJA. Intravenous immunoglobulin: effect on infertility and recurrent pregnancy loss. Israel Medical Association Journal (IMAJ)2007; 9: 877–880.
103.
Moraru M, Carbone J, Alecsandru D, et al. Intravenous immunoglobulin treatment increased live birth rate in a Spanish of women with recurrent reproductive failure and expanded CD56[+] cells. Am J Reprod Immunol 2012; 68: 75–84.
104.
EnsomMHStephensonMD. A two-center study on the pharmacokinetics of intravenous immunoglobulin before and during pregnancy in healthy women with poor obstetrical histories. Hum Reprod2011; 26: 2283–228.
105.
NurmohamedMTDijkmansBA. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. Drugs2005; 65: 661–694.
106.
Ramos-CasalsMBrito-ZeronPMuñozS. Autoimmune diseases induced by TNF-targeted therapies. Medicine (Baltimore)2007; 86: 242–251.
107.
BongartzTSuttonAJSweetingMJ. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. Journal of American Medical Association (JAMA)2006; 295: 2275–2285.
108.
BerthelotJMDe BandtMGoupilleP. Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. Joint Bone Spine2009; 76: 28–34.
109.
SalmonJEAlpertD. Are we coming to terms with tumor necrosis factor inhibition in pregnancy?Arthritis Rheum2006; 54: 2353–235.
110.
RosnerIHaddadABoulmanN. Pregnancy in rheumatology patients exposed to anti-tumor [TNF]-alpha therapy. Rheumatology2007; 46: 1508–1509.
111.
BankLHB. Unexpected dramatic clinical response of psoriasis lesions and unexpected pregnancy in an infertile patient in response to treatment with anti-tumor necrosis factor monoclonal antibody for Crohn’s disease. Am J Gastroenterol2002; 97(Abstract): S260–S260.
112.
Ramos-CasalsMRoberto-Perez-AlvarezDiaz-LagaresC. Autoimmune diseases induced by biological agents: a double-edged sword?Autoimmun Rev2010; 9: 188–193.
113.
WingerEEReedJLAshoushS. Treatment with Adalimumab [HumiraR] and intravenous immunoglobulin improves pregnancy rates in women undergoing IVF. Am J Reprod Immunol2009; 61: 113–120.
114.
WingerEEReedJL. Treatment with tumor necrosis factor inhibitors and intravenous immunoglobulin improves live birth rates in women with recurrent spontaneous abortion. Am J Reprod Immunol2008; 60: 8–16.
115.
BeerAE. Th-1/Th-2 natural killer cell activation systemically and locally in the endometrium and therapeutic options. Am J Reprod Immunol2001; 45: 23–23.
116.
MangubatCPThakerPPCavalcanteM. Etanercept and immune treatment in multiple IVF failures. Am J Reprod Immunol2001; 45: 24–24.
117.
ChaouatGAssal-MelianiAMartalJ. IL-10 prevents naturally occurring fetal loss in the CBAxDBA/2 mating combination, and local defect in IL-10 production in this abortion-prone combination is corrected by in vivo injection of IFN-tau. J Immunol1995; 154: 426–428.
118.
ZhongXHShiWYMaAT. Effects of Radix scutellariae and Rhizoma atractylodis on LPS-induced abortion and the uterine IL-10 contents in mice. Am J Chin Med2008; 36: 141–148.
119.
ShawSMShahMKHWilliamsSG. Immunological mechanisms of pentoxifylline in chronic heart failure. Eur J Cardiol2009; XX: 113–118.
120.
LuDSongHLiY. Pentoxifylline for endometriosis. Cochrane Database Syst Rev2012; 1: CD007677–CD007677.
121.
CreusMFabreguesFCarmonaF. Combined laparoscopic surgery and pentoxifylline therapy for treatment of endometriosis-associated infertility: a preliminary trial. Hum Reprod2008; 23: 1910–1916.
Letur-KonirschHDelanianS. Successful pregnancies after combined pentoxifylline-tocopherol treatment in women with premature ovarian failure who are resistant to hormone replacement therapy. Fertil Steril2003; 79: 439–441.
124.
Perez-Sanchez C, Ruiz-Limon P, Aguirre MA, et al. Mitochondrial dysfunction in antiphospholipid syndrome: implications in the pathogenesis of the disease and effects of coenzyme Q10 treatment. Blood 2012; 119: 5859–5870.
125.
ArnsonYAmitalHShoenfeldY. Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis2007; 66: 1137–1142.
126.
Agmon-LevinNBlankMZandman-GoddardG. Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression. Ann Rheum Dis2011; 70: 145–150.
127.
HughesG. Hughes syndrome: the antiphospholipid syndrome -a clinical overview. Clin Rev Allergy Immunol2007; 32: 3–12.
128.
PierangeliSSVega-OstertagMEGonzalezEB. New targeted therapies for treatment of thrombosis in antiphospholipid syndrome. Expert Rev Mol Med2007; 9: 1–15.
129.
RaschiEBorghiMOGrossiC. Toll-like receptors: another player in the pathogenesis of the antiphospholipid syndrome. Lupus2008; 87: 214–220.
130.
SadeghiKWessnerBLaggnerU. Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur J Immunol2006; 36: 361–370.
131.
BroussasMCornillet- LevefrePPotronG. Adenosine inhibits tissue factor expression by LPS-stimulated human monocytes: involvement of the A3 adenosine receptor. Thromb Haemost2002; 88: 123–130.
132.
Burcuglu-O’RalAErkanDAshersonR. Treatment of catastrophic antiphospholipid syndrome with defibrotide: a proposed vascular endothelial cell modulator. J Rheumatol2002; 29: 2006–2011.
KinevAVRoubeyRAS. Tissue factor in the antiphospholipid syndrome. Lupus2008; 17: 952–958.
136.
RaschiEBorghiMOGrossiC. Toll-like receptors: another player in the pathogenesis of the anti-phospholipid syndrome. Lupus2008; 17: 937–942.
137.
LockhinMDKimMLaskinCA. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum2012; 64: 2311–2318.
